Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.

Yerxa BR, Mundasad M, Sylvester RN, Garden JC, Cooper M, Kellerman DJ.

Adv Exp Med Biol. 2002;506(Pt B):1251-7. No abstract available.

PMID:
12614062
[PubMed - indexed for MEDLINE]
2.

Diquafosol tetrasodium: a novel dry eye therapy.

Nichols KK, Yerxa B, Kellerman DJ.

Expert Opin Investig Drugs. 2004 Jan;13(1):47-54. Review.

PMID:
14680452
[PubMed - indexed for MEDLINE]
3.

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ.

Cornea. 2004 Nov;23(8):784-92. Erratum in: Cornea. 2007 May;26(4):514.

PMID:
15502479
[PubMed - indexed for MEDLINE]
4.

Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

Mundasad MV, Novack GD, Allgood VE, Evans RM, Gorden JC, Yerxa BR.

J Ocul Pharmacol Ther. 2001 Apr;17(2):173-9.

PMID:
11324984
[PubMed - indexed for MEDLINE]
5.

INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.

Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K.

J Ocul Pharmacol Ther. 2002 Aug;18(4):363-70.

PMID:
12222766
[PubMed - indexed for MEDLINE]
6.

Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.

Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K.

Invest Ophthalmol Vis Sci. 2001 Jan;42(1):96-100.

PMID:
11133853
[PubMed - indexed for MEDLINE]
Free Article
7.

Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease.

Lee JH, Ahn HS, Kim EK, Kim TI.

Cornea. 2011 Feb;30(2):175-9. doi: 10.1097/ICO.0b013e3181e9adcc.

PMID:
21045674
[PubMed - indexed for MEDLINE]
8.

Clinical trials of therapeutic ocular surface medium for moderate to severe dry eye.

Watson SL, Daniels JT, Geerling G, Dart JK.

Cornea. 2010 Nov;29(11):1241-6. doi: 10.1097/ICO.0b013e3181d82f5e.

PMID:
20697273
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome.

Sullivan LJ, McCurrach F, Lee S, Taylor HR, Rolando M, Marechal-Courtois C, Creuzot-Garcher C, Easty DL, Karabatsas C, Bingh Hoh M, Faschinger C, Laroche L.

Ophthalmology. 1997 Sep;104(9):1402-8.

PMID:
9307633
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.

Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K; Diquafosol Ophthalmic Solution Phase 2 Study Group.

Ophthalmology. 2012 Oct;119(10):1954-60. doi: 10.1016/j.ophtha.2012.04.010. Epub 2012 Jun 26.

PMID:
22739038
[PubMed - indexed for MEDLINE]
11.

Diquafosol ophthalmic solution for dry eye treatment.

Nakamura M, Imanaka T, Sakamoto A.

Adv Ther. 2012 Jul;29(7):579-89. doi: 10.1007/s12325-012-0033-9. Epub 2012 Jul 27. Review.

PMID:
22843206
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.

Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C.

Graefes Arch Clin Exp Ophthalmol. 2005 Jun;243(6):531-8. Epub 2004 Dec 17.

PMID:
15965673
[PubMed - indexed for MEDLINE]
13.

Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits.

Yerxa BR, Douglass JG, Elena PP, Caillaud T, Amar T, Edick C, Peterson WM.

Adv Exp Med Biol. 2002;506(Pt A):261-5. No abstract available.

PMID:
12613918
[PubMed - indexed for MEDLINE]
14.

Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye.

Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K.

Jpn J Ophthalmol. 2013 Sep;57(5):440-6. doi: 10.1007/s10384-013-0251-y. Epub 2013 Jun 6.

PMID:
23740285
[PubMed - indexed for MEDLINE]
15.

Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.

Barber LD, Pflugfelder SC, Tauber J, Foulks GN.

Ophthalmology. 2005 Oct;112(10):1790-4.

PMID:
16102833
[PubMed - indexed for MEDLINE]
16.

Glaucoma and dry eye.

Ali FS, Akpek EK.

Ophthalmology. 2009 Jun;116(6):1232. doi: 10.1016/j.ophtha.2008.12.034. No abstract available.

PMID:
19486808
[PubMed - indexed for MEDLINE]
17.

Minimal clinically important difference for the ocular surface disease index.

Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, Asbell PA, Pflugfelder SC.

Arch Ophthalmol. 2010 Jan;128(1):94-101. doi: 10.1001/archophthalmol.2009.356.

PMID:
20065224
[PubMed - indexed for MEDLINE]
18.

[A molecular marker for dry eye].

Pintor J.

Arch Soc Esp Oftalmol. 2007 Mar;82(3):129-30. Spanish. No abstract available.

PMID:
17357887
[PubMed - indexed for MEDLINE]
Free Article
19.

Assessment and treatment of the dry eye in leprosy.

Passerotti S, Salotti RA, Vieth H.

Indian J Lepr. 1998 Jan-Mar;70(1):103-8.

PMID:
9598411
[PubMed - indexed for MEDLINE]
20.

[Analysis of incidence of ocular surface disease index with objective tests and treatment for dry eye].

Rodríguez-Torres LA, Porras-Machado DJ, Villegas-Guzmán AE, Molina-Zambrano JA.

Arch Soc Esp Oftalmol. 2010 Feb;85(2):70-5. Spanish.

PMID:
20566178
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk